Medpace Holdings, Inc.
Financials
Valuation Metrics
Medpace Holdings, Inc.'s Market Cap is $16.37B. At end of 2025 it was $15.89B. Ranked #690 of 3,112 in US market (top 22%), #214 of 1,445 on NASDAQ (top 15%), #44 of 206 in Health Care Equipment & Services (top 21%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $16.37B | US#690/3,112 Sec#44/206 |
| Revenue | $2.78B | US#1,286/3,112 Sec#78/206 |
| Net Income | $492M | US#824/3,112 Sec#45/206 |
| Total Assets | $2.06B | US#2,044/3,112 Sec#103/206 |
| Net Assets | $434M | US#2,358/3,112 Sec#127/206 |
| Employees | 6,200 | US#756/3,112 Sec#68/206 |
| Value | ||
| P/E | 33.31x | US#1,549/3,112 Sec#58/206 |
| P/B | 37.73x | US#2,903/3,112 Sec#197/206 |
| PEG | 0.97x | US#819/3,112 Sec#33/206 |
| P/S | 5.88x | US#2,371/3,112 Sec#167/206 |
| EV/EBITDA | 26.55x | US#2,092/3,112 Sec#111/206 |
| FCF Yield | 4.67% | US#1,353/3,112 Sec#74/206 |
| Profitability | ||
| ROE | 113.29% | US#19/3,112 Sec#2/206 |
| ROA | 23.89% | US#52/3,112 Sec#2/206 |
| Op. Margin | 20.97% | US#858/3,112 Sec#27/206 |
| Revenue Growth | 17.24% | US#859/3,112 Sec#56/206 |
| Earnings Growth | 34.46% | US#713/3,112 Sec#31/206 |
| Financial Health | ||
| Debt Ratio | 374.16% | US#2,253/3,112 Sec#180/206 |
| Total Debt | $120M | US#2,333/3,112 Sec#129/206 |
| FCF | $764M | US#668/3,112 Sec#43/206 |
| Cash | $503M | US#1,065/3,112 Sec#61/206 |
| Current Ratio | 0.73x | US#2,561/3,112 Sec#204/206 |
| Net Debt/EBITDA | -0.64x | US#408/3,112 Sec#28/206 |
| Performance | ||
| 1Y Return | 35.48% | US#1,124/3,112 Sec#72/206 |
| 1M Return | 2.80% | US#1,244/3,112 Sec#90/206 |
| From 52W High | -15.45% | US#1,441/3,112 Sec#101/206 |
| 1Y MDD | -36.61% | US#1,782/3,112 Sec#91/206 |
| Trading | ||
| Volume | 209,409 shares | US#2,637/3,112 Sec#185/206 |
| Trading Value | $121M | US#801/3,112 Sec#64/206 |
| Per Share | ||
| EPS | $15.95 | US#114/3,112 Sec#11/206 |
| BPS | $16.23 | US#1,407/3,112 Sec#81/206 |
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.